Pfizer (NYSE:PFE) Trading 0.8% Higher – Should You Buy?

Pfizer Inc. (NYSE:PFE) rose 0.8% during mid-day trading on Tuesday . The company traded as high as $26.34 and last traded at $26.26. Approximately 6,990,184 shares were traded during trading, a decline of 80% from the average daily volume of 35,704,997 shares. The stock had previously closed at $26.05.

Analyst Upgrades and Downgrades

Several brokerages have commented on PFE. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday. Finally, Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Performance

The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock’s fifty day moving average is $26.22 and its two-hundred day moving average is $27.10. The firm has a market capitalization of $148.37 billion, a price-to-earnings ratio of 18.58, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the firm earned $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Activity

In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On Pfizer

A number of institutional investors have recently modified their holdings of the business. 111 Capital bought a new stake in Pfizer in the 4th quarter valued at about $509,000. Thoma Capital Management LLC bought a new position in Pfizer during the 4th quarter worth $523,000. PKO Investment Management Joint Stock Co bought a new stake in shares of Pfizer during the 4th quarter valued at $2,096,000. Northstar Financial Companies Inc. bought a new position in shares of Pfizer in the fourth quarter worth $854,000. Finally, Wealthedge Investment Advisors LLC bought a new stake in Pfizer during the fourth quarter worth about $207,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.